Cutting-Edge Dermatology: From Atopic Models to HPV Insights

1. Advantages and limitations of in vitro models for atopic dermatitis: A consensus expert opinion.
Authors: Peters RHW, Smits JPH, van den Bogaard EH, et al.
Journal: The Journal of investigative dermatology, 2026 Oct
PMID: 42246919
DOI: 10.1016/j.jid.2026.04.032


2. Beyond cervicovaginal limitations: potential bidirectional interactions between HPV infection and mucosal microbiota from oral, anorectal and penile sites - a mini-review.
Authors: Liu W, Yu Q, Xue X
Journal: Frontiers in cellular and infection microbiology, 2026
PMID: 42840393
DOI: 10.3389/fcimb.2026.1962165


3. International Dermoscopy Society consensus recommendations for the management of lentigo maligna.
Authors: Forsea AM, Pampena R, Akay BN, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Oct
PMID: 41854120
DOI: 10.1111/jdv.70406


4. Case Report: Nicotinamide monotherapy for infantile bullous pemphigoid with long-term follow-up.
Authors: Qu P, Zhou G, Yang B
Journal: Frontiers in immunology, 2026
PMID: 42835264
DOI: 10.3389/fimmu.2026.1935375


5. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.
Authors: Stein Gold L, Armstrong AW, Soung J, et al.
Journal: The British journal of dermatology, 2026 Sep 18
PMID: 42397072
DOI: 10.1093/bjd/ljag264


6. Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.
Authors: Passeron T, Pandya AG, Ezzedine K, et al.
Journal: Advances in therapy, 2026 Oct
PMID: 42440041
DOI: 10.1007/s12325-026-03673-6


7. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
Authors: Pezzolo E, Luyo Saboya RA, Ortoncelli M, et al.
Journal: Acta dermato-venereologica, 2026 Oct 7
PMID: 42839349
DOI: 10.2340/actadv.v106.adv-2026-0765


8. The Role of Tissue Resident Memory Cells in Immunodermatological Disorders.
Authors: De A, Chakraborty D, Desai S, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 42473984
DOI: 10.1111/ijd.70594


9. HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.
Authors: Burmann SN, Wieland U, Silling S, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 41047841
DOI: 10.1111/ddg.15981


10. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
Authors: Hauschild A, Hassel JC, Ziemer M, et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 Oct
PMID: 42579833
DOI: 10.1200/JCO-26-00852